On Wednesday, Portola Pharmaceuticals PTLA will release its latest earnings report. Here is Benzinga's outlook for the company.
Earnings and Revenue
Analysts covering Portola Pharmaceuticals have modeled for quarterly EPS loss of $1.36 on revenue of $6.2 million.
In the same quarter last year, Portola Pharmaceuticals reported a loss per share of 95 cents per share on sales of $13.69 million. The Wall Street consensus estimate for earnings would represent a 43.16 percent increase for the company. Sales would be down 54.72 percent from the year-ago period.
Portola Pharmaceuticals's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -1.46 | -0.98 | -0.69 | -1.09 |
| EPS Actual | -1.41 | -1.22 | -0.74 | -0.95 |
Stock Performance
Over the last 52-week period, shares of Portola Pharmaceuticals are up 36.3 percent. Analysts' have adjusted their estimates lower for EPS and revenues over the past 90 days.
Analysts generally rate Portola Pharmaceuticals stock as Neutral. The strength of this rating has maintained conviction over the past three months.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
